Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Caspase-3 examination panel

From: TNFα induces Caspase-3 activity in hematopoietic progenitor cells CD34+, CD33+, and CD41 + of myelodysplastic syndromes

Tubea

Treatment

Fluorochrome antibody

1

Without exposure

Negative control

2

Cisplatin 100 µg/(10 µL)

Positive control

3

Without exposure

CD34 APC, CD40 PE, CD154 FITC

4

Without exposure

CD34 APC, Caspase-3 FITC

5

rhTNFα 48 ng

CD34 APC, Caspase-3 FITC

6

Without exposure

CD33 PE, Caspase-3 FITC

7

rhTNFα 48 ng/well

CD34 APC, CD33 PE, Caspase-3 FITC

8

Without exposure

CD41 PE, Caspase-3 FITC

9

rhTNFα 48 ng/well

CD34 APC, CD41a PE, Caspase-3 FITC

10

Without exposure

CD73 PE, Caspase-3 FITC

11

rhTNFα 48 ng/well

CD34 APC, CD73 PE, Caspase-3 FITC

  1. aEach tube contains BMMC with density of 300,000 cells/300µL media
Back to article page

BMC Molecular and Cell Biology

ISSN: 2661-8850

Contact us